You searched for "Tumours"

733 results found

The College of Optometrists calls for shift in detecting and managing glaucoma

The College of Optometrists calls for shift in detecting and managing glaucoma by fully unlocking safe and effective primary care capacity Glaucoma is the second leading cause of irreversible sight loss in the UK and affects over one million people,...

What can artificial intelligence do to improve sustainability in the delivery of ophthalmic care?

The 2025 NHS 10-year plan, titled ‘Fit for the Future’, emphasises a significant shift from analogue to digital, with a strong focus on integrating AI and other technologies to transform healthcare. The plan aims to make the NHS the "most...

Will COVID-19 impact the selection of ophthalmology as a career choice by medical students?

The COVID-19 pandemic has had profound effects on medical education and has called for large shifts in the medical curriculum. Clinical attachments were suspended at the height of the pandemic and examinations were cancelled or were moved to an online...

The International Centre for Eye Health: weaving the global threads together

The VISION 2020 LINKS & Networks Programme has been writing regular articles in Eye News about its capacity-strengthening activities in low- and middle-income countries (LMICs) for more than a decade. This, the first International Issue, is a landmark for Eye...

The invisible touch: a VISION 2020 LINK with Indonesia

Indonesia’s population, the world’s fourth largest, is spread across 6,000 inhabited islands. Whilst some areas (e.g. Kalimantan, Papua) are relatively sparsely populated, Java is the world’s most densely populated island, with twice the population of the UK in half the...

Increasing access to eye care through community outreach clinics in Uganda

There has been a VISION 2020 LINK between Mulago Hospital and Makerere University in Kampala, Uganda and the Royal Free Hospital, London, since 2010. There have been regular training visits between teams from the eye departments at Mulago and the...

Diabetic Retinopathy Network laser training programme

The VISION 2020 Diabetic Retinopathy Network (DR-NET) was established in 2014 to tackle the increasing burden of diabetes and diabetic retinopathy (DR) in developing countries [1]. By forming a network of long-term LINK capacity-building partnerships, learning and best practice can...

The Diabetic Eye Screening Programme in Tanzania - The VISION 2020 LINK between Dodoma and Belfast

Rahila Bashir, Senior Remote Ophthalmic Research Image Grader, talks to Frank Sandi, Ophthalmologist at the Benjamin Mkapa Hospital (BMH), University of Dodoma in Tanzania and to Tunde Peto at Queen’s University Belfast (QUB) and Belfast Health and Social Care Trust...

DR-NET Workshop – information-sharing for strengthening DR programmes

Contributors: Rosie Brennan, Anshul Chauhan, Mona Duggal, John Ellis, Michael Gichangi, Edwin Grayson, Catherine Jamieson, Ankita Kankaria, Oliver Kemp, Hendra Kusuma, Nanda Matthew, Geeta Menon, Habibah Muhiddin, Tunde Peto, Recivall Salongcay, Frank Sandi, Hazel Shillingford-Ricketts, Bernadetha Shilio, Caroline Styles, Sharon...

Preventing blindness from diabetes: planning a programme of service development and research across Malawi

In sub-Saharan Africa 19.4 million people have diabetes; this is projected to rise to 28.6 million by 2030 [1]. Sight loss from diabetes devastates the lives of working people, affecting the financial stability of the families and communities who depend...

End of an era: completing training. Tips for survival, fellowship applications and how to CCT

Tafadzwa Young-Zvandasara shares the things he wishes he had paid more attention to when approaching the end of training. It is the end of an era, you are now ready to move on. Training has been filled with a structured...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...